doi:10.19983/j.issn.2096-8493.20220107

Abstract

CLC Number:

References 35

[1]	Bates M, O’Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis, 2013, 13(1):36-42. doi: 10.1016/S1473-3099(12)70245-1. doi: 10.1016/S1473-3099(12)70245-1 URL
[2]	Swindells S, Ramchandawi R, Gupta A, et al. One Moth of Rifapentine plus Isoniazid to prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi: 10.1056/NEJMoa1806808. doi: 10.1056/NEJMoa1806808 URL
[3]	Nemes E, Geldenhuys H, Rozot V, et al. tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi: 10.1056/NEJMoa1714021. doi: 10.1056/NEJMoa1714021 URL
[4]	Ottenhoff THM. A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2020, 382(16):1576-1577. doi: 10.1056/NEJMc2001364. doi: 10.1056/NEJMc2001364 URL
[5]	Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020, 20(3)e28-e37.doi: 10.1016/S1473-3099(19)30625-5. doi: 10.1016/S1473-3099(19)30625-5
[6]	Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018, 23(4):359-368. doi: 10.1111/resp.13245. doi: 10.1111/resp.13245 URL
[7]	World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization,2019.
[8]	Elhadi M, Khaled A, Msherghi A. Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. Infect Agent Cancer, 2021, 16(1):72. doi: 10.1186/s13027-021-00413-z. doi: 10.1186/s13027-021-00413-z URL
[9]	Lin CH, Lin CJ, Kuo YW, et al. Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis, 2014, 14:5. doi: 10.1186/1471-2334-14-5. doi: 10.1186/1471-2334-14-5 URL
[10]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[11]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X
[12]	Shu CC, Liao KM, Chen YC, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep, 2019, 9(1):11901. doi: 10.1038/s41598-019-48395-8. doi: 10.1038/s41598-019-48395-8 URL
[13]	Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest, 2014, 145(6):1286-1297. doi: 10.1378/chest.13-2137. doi: 10.1378/chest.13-2137 URL
[14]	Hu HY, Wu CY, Huang N, et al. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiol Infect, 2014, 142(1):191-199. doi: 10.1017/S0950268813000551. doi: 10.1017/S0950268813000551 pmid: 23510593
[15]	Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis, 2009, 48(12):1657-1665. doi: 10.1086/599035. doi: 10.1086/599035 pmid: 19445585
[16]	Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One, 2017, 12(3):e0173250. doi: 10.1371/journal.pone.0173250. doi: 10.1371/journal.pone.0173250
[17]	Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol, 2020, 115(3):340-349. doi: 10.14309/ajg.0000000000000527. doi: 10.14309/ajg.0000000000000527 URL
[18]	Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol, 2020, 39(5):1439-1447. doi: 10.1007/s10067-019-04866-x. doi: 10.1007/s10067-019-04866-x URL
[19]	Hosseini M, Shakerimoghaddam A, Ghazalibina M, et al. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries; A systematic review and meta-analysis of cross-sectional studies. Microb Pathog, 2020, 141:104018. doi: 10.1016/j.micpath.2020.104018. doi: 10.1016/j.micpath.2020.104018 URL
[20]	Wong RJ, Hubbard A, Bagley L, et al. Estimating Prevalence of Hepatitis B Virus Coinfection Among Adults With Tuberculosis: A Systematic Review With Meta-analysis. J Clin Gastroenterol, 2022, 56(7):601-617. doi: 10.1097/MCG.0000000000001533. doi: 10.1097/MCG.0000000000001533 URL
[21]	Behzadifar M, Heydarvand S, Behzadifar M, et al. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci, 2019, 29(1):945-956. doi: 10.4314/ejhs.v29i1.17. doi: 10.4314/ejhs.v29i1.17 pmid: 30700963
[22]	姚琳, 顾斌斌, 王霞芳, 等. 苏州地区2011年—2017年间9528例肺结核患者合并症的原因分析及其分布趋势. 抗感染药学, 2019, 16(2):258-261. doi: 10.13493/j.issn.1672-7878.2019.02-025. doi: 10.13493/j.issn.1672-7878.2019.02-025
[23]	邓岚兰, 杨新婷, 贾俊楠, 等. 2012—2016年北京市胸科医院肺结核合并症患者的回顾性分析. 疾病监测, 2018, 33(4):320-323.
[24]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[25]	World Health Organization.World Health Statistics 2019.Geneva:World Health Organization, 2019.
[26]	The World Bank New World Bank country classifications by income level:2020-2021:[EB/OL].[2022-06-11]. https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2020-2021.
[27]	Sbrana E, Grise J, Stout C, et al. Co-morbidities associated with tuberculosis in an autopsy case series. Tuberculosis (Edinb), 2011, 91 Suppl 1:S38-42. doi: 10.1016/j.tube.2011.10.008. doi: 10.1016/j.tube.2011.10.008
[28]	Drug Interactions Checker[DB/OL].[2022-06-12]. https://www.drugs.com/drug_interactions.html.
[29]	Tao NN, Li YF, Song WM, et al. Risk factors for drug-resis-tant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China,during 2004—2019. BMJ Open, 2021, 11(6):e044349. doi: 10.1136/bmjopen-2020-044349. doi: 10.1136/bmjopen-2020-044349
[30]	何燕超, 揭志军. 综合医院活动性肺结核的早期筛查的进展与策略. 结核与肺部疾病杂志, 2022, 4(4):334-337. doi: 10.19983/j.issn.2096-8493.20220078. doi: 10.19983/j.issn.2096-8493.20220078
[31]	周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展. 结核与肺部疾病杂志, 2022, 4(4):338-342. doi: 10.19983/j.issn.2096-8493.20220013. doi: 10.19983/j.issn.2096-8493.20220013
[32]	钱晓文, 翟晓文. 造血干细胞移植与结核病. 结核与肺部疾病杂志, 2022, 4(4):315-319. doi: 10.19983/j.issn.2096-8493.20220092. doi: 10.19983/j.issn.2096-8493.20220092
[33]	张晓林, 李锋. 肺结核致呼吸衰竭研究进展. 结核与肺部疾病杂志, 2022, 4(4):320-324. doi: 10.19983/j.issn.2096-8493.20220014. doi: 10.19983/j.issn.2096-8493.20220014
[34]	郦源, 郭茹茹, 吕良敬. 结缔组织病合并结核病的研究进展. 结核与肺部疾病杂志, 2022, 4(4):309-314. doi: 10.19983/j.issn.2096-8493.20220011. doi: 10.19983/j.issn.2096-8493.20220011
[35]	刘玉坤, 郭智. 慢性髓系白血病与结核病. 结核与肺部疾病杂志, 2022, 4(4):325-327. doi: 10.19983/j.issn.2096-8493.20220108. doi: 10.19983/j.issn.2096-8493.20220108

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gulimina·Abulimiti , Maiweilanjiang·Abulimiti , Diermulati·Tusun , Liu Zhenjiang, He Yi, Su Wei, Ou Xichao. Analysis of influencing factors of rifampicin resistance in pulmonary tuberculosis patients in Kashgar in 2021 [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 269-273.
[2]	Yang Zhen, Lei Nan, Zhao Fei, He Yanping, Lin Na, Zhang Zhiguo. Investigation on latent infection of Mycobacterium tuberculosis among freshmen in Colleges and universities in Changping District of Beijing and analysis of preventive treatment effect of latent infection [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 274-280.
[3]	Dong Zhaoliang, Yao Liming, Li Lingdi, Wang Lianbo, Yao Xiaowei, Li Zhuo, Liu Fengsheng, Jia Chenguang. Clinical efficacy of conservative treatment for mild spinal tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 281-286.
[4]	Li Yishuai, Qin Xuebo, Li Xianglan, Wei Lan, Duan Xiaoliang, Zhang Lei, Chen Liang, Li Jianhang. Analysis of effect of video-assisted thoracoscopic surgery versus thoracotomy in the treatment of refractory cavity pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 292-295.
[5]	Li Junxia, Meng Yizhe, Zhang Yanan, Chen Yanqiang, Zhao Qing. Clinical features and MRI characteristics of 12 cases of tuberculous radiculomyelitis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 296-299.
[6]	Hu Juan, Zhou Yan, Yang Chengqing. Correlation analysis of psychological condition like anxiety/depression and electronic bronchoscope treatment adherence in bronchial tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 305-308.
[7]	Li Yuan, Guo Ruru, Lyu Liangjing. Research progress of connective tissue disease and tuberculosis comorbidity [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 309-314.
[8]	Qian Xiaowen, Zhai Xiaowen. Hematopoietic stem cell transplantation and tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 315-319.
[9]	Zhang Xiaolin, Li Feng. Research progress of respiratory failure caused by pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 320-324.
[10]	Liu Yukun, Guo Zhi. Research progress of chronic myeloid leukemia complicated with tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 325-327.
[11]	He Yanchao, Jie Zhijun. Strategy of early screening for active pulmonary tuberculosis in general hospital [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 334-337.
[12]	Zhou Yinan, Zhu Huili. Research progress of chronic obstructive pulmonary disease complicated with pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 338-342.
[13]	GONG Dao-min, ZHU Ling, TIAN Tian, ZHONG Zhen. Analysis of influencing factors of premonitory sadness in lung cancer patients complicated with pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(3): 193-197.
[14]	ZHANG Yan-kun, GUAN Yan, HAN Zhao, ZHANG Zhi-hua. Clinical characteristics of 18 cases of tuberculous posterior uveitis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(3): 216-221.
[15]	ZHANG Yan-kun, GUAN Yan, ZHAI Jing-jie, HAN Zhao. Application of anti-neovascular endothelial growth factor therapy in tuberculous chorioretinopathy: a case report and literature review [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(3): 222-226.